ENThe cost of leukaemia treatment in Germany cannot be given as one figure: it depends on the form of the disease and whether a transplant is needed, and only the hospital’s written estimate states the amount. People ask when the diagnosis is made and the clock is running — not out of curiosity, but to know whether treatment is possible for their family. Anyone quoting a price without seeing the records is selling confidence, not a calculation.
Below are the blocks the bill is made of, why it varies several-fold with one diagnosis, what an official German estimate looks like and what it leaves out. The methods are covered on the page about leukaemia treatment in Germany.
Why the same diagnosis produces very different figures
The figures differ because one diagnosis covers different forms, different work already done and different medical decisions. Leukaemia is a cancer of the blood-forming system, and the cost depends above all on its form. Acute lymphoblastic, acute myeloid, chronic myeloid and chronic lymphocytic leukaemia are four spending scenarios: one needs immediate admission for weeks, another tablets and monitoring.
The second factor is what has been done at home. A patient with a complete set of recent results, genetics included, pays mainly for treatment; one with a single discharge letter pays for the whole work-up again.
The third factor is age, the state of the other organs and whether a transplant is indicated. The tumour board may decide that an intensive course is not advisable in the patient’s condition and choose another treatment — then the estimate is rebuilt around a new plan.
Diagnostics: the first block, billed separately
Diagnostics usually appear in the estimate as a separate item: without them, treatment can only be costed roughly. Even with results from home, the department normally repeats the essentials: a full blood count, bone marrow aspiration and often a trephine biopsy — a thin core of bone — microscopy of the cells, and immunophenotyping by flow cytometry, which shows which cell line the leukaemia comes from.
The second part is genetics: cytogenetics and the karyotype, FISH, PCR for the characteristic rearrangements and a next-generation sequencing (NGS) panel. These tests show whether a targeted drug will help, and the same markers later track residual disease, leukaemia cells left after treatment that a microscope cannot see. The German guideline on acute myeloid leukaemia advises starting treatment once these results are available, if the patient’s condition allows.
The third part is HLA typing — the tissue match — of the patient and close relatives if a transplant is considered, a check of heart and kidneys before high doses, and a search for hidden infection. This block usually takes a few days, and its result changes everything that follows: the drugs, the number of cycles and the need for a transplant.
Treatment: cycles, drugs, transplantation
Treatment is the largest part of the bill. Induction chemotherapy for the acute forms — see leukaemia chemotherapy in Germany — means weeks as an inpatient rather than a weekly infusion, much of it while the patient has almost no blood cells of their own. Hence the single room with filtered air, antibiotics and antifungals, transfusions and, if needed, growth factors — and this supportive care, together with the hospital days, often outweighs the chemotherapy itself in the bill.
The second block is the drugs that changed both outlook and price: tyrosine kinase inhibitors in chronic myeloid and Philadelphia-positive acute lymphoblastic leukaemia, targeted agents chosen on the genetics, and antibodies. Some are taken for years, so the unit of cost is a month of treatment with its check-ups, not a cycle.
The third block is allogeneic, or donor, stem cell transplantation and cell therapy. Its bill covers the donor search in the registry, collection and transport of the graft, high-dose conditioning, the transplant itself and months of follow-up, including treatment of graft-versus-host disease, when donor cells attack the patient’s tissues. See bone marrow transplant in Germany and the cost of a bone marrow transplant in Germany. CAR-T cell therapy in Germany is costed separately and given only on strict indications.
How to obtain a price and what to read in the estimate
The only document to plan around is the Kostenvoranschlag, the hospital’s official estimate on its letterhead, issued after the department has reviewed the records; anything quoted earlier is guesswork. For prices across oncology, see cancer treatment prices in Germany.
Inpatient care is paid through the DRG system: each hospital case has a rate from the federal catalogue, with separate case groups for transplantation. On top come daily payments for nursing care, supplementary fees (Zusatzentgelte) for especially expensive drugs and procedures, and payment for new methods not yet in the catalogue, which covers part of cell therapy. Doctors’ services outside the rate — outpatient consultations and tests, and treatment by the head of department if chosen in writing in advance — are billed on the official GOÄ fee scale. So check what the case rate includes and what comes on top.
| Cost item | Depends on | Guide figure |
|---|---|---|
| Diagnostics and genetics | tests done at home | per hospital estimate |
| Chemotherapy cycles | cycles and inpatient days | per hospital estimate |
| Supportive care | infections, transfusions | per hospital estimate |
| Targeted drugs | drug and duration | per hospital estimate |
| Transplantation | donor, conditioning, follow-up | per hospital estimate |
| Doctors’ services under GOÄ | consultations, optional services | per hospital estimate |
The estimate usually leaves out the deposit terms and refund of the balance, treatment after discharge, drugs to take home, a companion’s accommodation, the interpreter, transport between hospitals and repeat check-ups. In acute leukaemia it is provisional by definition: the number of cycles depends on the response to the first, and the calculation is updated after each stage.
Frequently asked questions
How much does blood cancer treatment cost in Germany?
There is no single price: it depends on the diagnosis, its form and the treatment plan, and only the hospital’s estimate states it. «Blood cancer» usually means leukaemia, the subject of this page; lymphomas and myeloma have their own treatment schemes and costs.
Can I get a price for leukaemia treatment before coming to Germany?
Yes, if the records are sent in advance: from them the haematology department draws up a written estimate, the Kostenvoranschlag. Complete records make it more precise and spare repeat tests. In acute leukaemia it stays provisional, because the number of cycles and inpatient days depends on the response to the first cycle.
Why can the final bill differ from the estimate?
Because the estimate describes the expected course and the bill the actual one. Infections, complications, extra hospital days, transfusions and drugs change it, and in acute leukaemia so does the decision on the next cycle or a transplant. After discharge, any deposit is settled against the services provided: a shortfall is paid, a surplus refunded under the contract.
How AlenMed arranges treatment
AlenMed collects and translates the records, sends them to a haematology department, obtains the estimate and explains every line of it, prepares the visa invitation and provides a medical interpreter; in acute leukaemia all of this is urgent. Possible addresses include the Department of Internal Medicine I at Freiburg University Hospital, headed by Professor Justus Duyster, also clinical director of the Freiburg cancer centre; the Department of Internal Medicine III at the Klinikum rechts der Isar in Munich under Professor Florian Bassermann; and the haematology and oncology department of the Red Cross Hospital in Munich, led by Professor Marcus Hentrich.
The patient takes home a written plan with the expected number of cycles, a discharge summary with the protocol, prescriptions for treatment at home and follow-up dates.
This material is for information only and is not an offer. The extent of treatment is decided by a doctor at an in-person consultation.